Tazarotene
![]() | |
Clinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | >99% |
Elimination half-life | 19 Hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.115.380 |
Chemical and physical data | |
Formula | C21H21NO2S |
Molar mass | 351.463 g/mol g·mol−1 |
Tazarotene (marketed as Tazorac®, Avage® and Zorac®) is a prescription topical retinoid sold as a cream or gel. This medication is approved for treatment of psoriasis, acne, and sun damaged skin (photodamage). It is commonly sold in two concentrations: 0.05% and 0.1%.
Common side effects include worsening of acne, dry skin, itchiness, redness and in some cases extreme drying and cracking of skin. For most patients these side effects are uncomfortable but mild and decrease markedly after the first 2–4 weeks of use.
For best results dermatologists recommend applying the cream or gel once daily before bedtime after washing the face with a mild soap. Dermatologists recommend using a moisturizer with tazarotene so skin will not be as dry and flaky.